Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2020, with a specific reporting date of March 9, 2020. The document serves as a transaction notification regarding insider trading activities rather than a financial performance report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the transaction price of American Depositary Shares (ADSs) at $42.53 per share.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a specific transaction involving the purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR) and a Person Closely Associated (PCA).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a single transaction event.
Important Facts for Investors
- Transaction Type: Purchase of 1,570 American Depositary Shares (ADSs).
- Parties Involved: Ms. D Conrad (SVP, Human Resources) and Mr. C J Conrad (PCA).
- Transaction Date: March 5, 2020.
- Price and Volume: Shares were purchased at $42.53 each on the New York Stock Exchange (XNYS).
- Financial Data: No revenue, earnings, or balance sheet data is included in this specific filing.